Introduction
Triple-negative breast cancer (TNBC), which accounts for approximately 10-15% of all breast tumors, is an aggressive breast cancer subtype defined through biomarker analysis by the absence of estrogen (ER) and progesterone (PR) receptor expression and lack of epidermal growth factor receptor-2 (HER2) overexpression and/or amplification.
Due to the absence of expression of these receptors, no effective therapy is currently available for TNBC patients, which typically present a high rate of tumor relapse compared with patients with other subtypes of breast cancer (Carey et al. 2006 , Haffty et al. 2006 , Dent et al. 2007 , O'Brien et al. 2010 . With the recent use of genome-wide expression analysis, breast cancer has also been classified into various molecular subtypes. The initial classification, currently known as the 'intrinsic subtypes' and defined by the PAM50 assay, includes the luminal A, luminal B, HER2-enriched and basallike groups (Perou et al. 2000 , Prat et al. 2012 . Tumors of the basal-like category are usually negative for ER, PR and HER2, and thus overlap with the biomarker-defined TNBC group (Metzger-Filho et al. 2012) . Several reports have now demonstrated that these tumors frequently exhibit features of tumor-initiating cells (also designated as cancer stem cells), upregulation of mesenchymal markers and downregulation of epithelial markers, thus suggesting a possible link between the phenomenon of epithelial-mesenchymal transition (EMT) and TNBC (Gupta & Massague 2006 , Sarrio et al. 2008 , Jeong et al. 2012 . EMT has been associated with a more invasive or metastatic tumor behavior and with the acquisition of resistance to a variety of anticancer therapies, including chemotherapy, radiation, small molecule-targeted therapies and immunotherapy (Thiery & Sleeman 2006 , Creighton et al. 2009 , Kalluri & Weinberg 2009 , Larocca et al. 2013 , Hamilton et al. 2014 , Fernando et al. 2016 ).
Brachyury (encoded by the gene T) (Kispert et al. 1995 ) is a transcription factor that induces EMT in human carcinoma cells (Fernando et al. 2010) and whose expression has been reported to associate with poor prognosis in several human cancers including prostate (Pinto et al. 2014) , lung (Haro et al. 2013) , colon (Kilic et al. 2011) and breast (Palena et al. 2014b , Shao et al. 2015 among others. Our group has previously reported on an increased proportion of brachyury-expressing breast carcinomas negative for ER and PR (Palena et al. 2014b ). However, a limited sample number precluded the evaluation of brachyury in the TNBC subgroup. In this study, the expression of brachyury was analyzed in primary and metastatic TNBC tumors using both in silico and immunohistochemical analyses. Increased frequency of samples positive for brachyury mRNA expression was observed in TNBC compared with other breast cancer subtypes. Furthermore, brachyury mRNA expression levels inversely correlated with the levels of mRNA encoding for ER-α (ESR1) and PR (PGR) receptors. Immunohistochemical analysis of primary and metastatic TNBC biopsies also demonstrated variable levels of brachyury protein expression in primary and metastatic TNBC lesions. Furthermore, a strong association was observed between nuclear brachyury expression and stage of disease, with nuclear brachyury also being predominant in metastatic vs primary TNBC tumors. An association was also observed between high levels of brachyury in primary tumors and poor prognosis.
There are currently two brachyury-targeting cancer vaccines undergoing clinical evaluation (Heery et al. 2015b ) (www.clinicaltrials.gov/ct2/show/NCT02179515). The data presented here provide a rationale for using brachyury-targeting immunotherapy approaches for the treatment of TNBC.
Methods

Tumor cell lines
Tumor cell lines were purchased from the American Tissue Culture Collection (ATCC), which uses STR analysis for identity verification. Cells were grown in DMEM medium (Corning) supplemented with 10% fetal bovine serum (Gemini Bio-Products), 1X antibiotic/antimycotic solution (Corning) and 4 μg/mL recombinant human insulin (Gibco). Cell lines were used for experiments at the following passages from purchased stocks: MDA-MB-231, passage 6; MDA-MB-436, passage 4; Hs 578T, passage 6; BT-474, passage 2; ZR-75-1, passage 4; and MCF7, passage 1.
Patients and tissue collection
Seventy-seven patients with histologically diagnosed primary TNBC and ten patients with metastatic TNBC were enrolled in the Inter-Institutional Multidisciplinary BioBank of the Biomarker Discovery and Advanced Technologies (BioDAT) Laboratory, IRCCS San Raffaele Pisana, Rome, Italy. In collaboration with the Surgical and Pathology Departments of San Giovanni Addolorata Hospital and the Medical Oncology Unit of the 'Tor Vergata' Clinical Center, Rome, Italy, primary breast and metastatic tumor tissue samples were collected at the time of surgery. Patient characteristics are provided in Table 1 . Clinical follow-up data were available from 58 of 77 patients with primary TNBC. Patients received the following treatment regimens: 30 of 58 received anthracycline-based therapy; 4 of 58 received 23:10 non-anthracycline-based regimens (CMF); 5 of 58 received adjuvant radiotherapy alone; 8 of 58 did not receive treatment and treatment data were not available for the remaining 11 of 58 patients. Informed consent was obtained from each participating subject. The study was performed under the appropriate institutional ethics approval and in accordance with the principles embodied in the Declaration of Helsinki.
Immunohistochemical detection of brachyury
Sections of formalin-fixed, paraffin-embedded tissues were evaluated for brachyury expression by using a rabbit monoclonal anti-brachyury antibody (MAb 54-1) at a 1:500 dilution . Staining was performed on the Ventana BenchMark XT automated staining platform with the UltraView Universal DAB Detection Kit (Roche) according to manufacturer's instructions. Two pathologists independently evaluated the tumor and normal tissue samples in a blinded, randomized manner. For each slide, three to five random fields were evaluated; for each field, the percentage of positive tumor cells was calculated as: ((number of positive tumor cells/total number of tumor cells) × 100). Nuclear, cytoplasmic and total brachyury staining was independently scored, with brachyury being observed either in the nucleus, the cytosol or both compartments of the tumor cells. For calculation of total brachyury expression (Table 2) , the percentage of tumor cells with mutually exclusive cytosolic or nuclear staining was added. Tumor cells showing brachyury in both compartments were scored only once. The relative staining intensity was scored as weak (+) for pale brown intensity, moderate (++) for intermediate brown intensity and strong (+++) for intense, dark brown immunoprecipitate. Immunoreactivity index was calculated by multiplying the percentage of positive cells by the staining intensity. For normal tissues, the percentage of reactivity was individually evaluated for each cell type and calculated as: ((number of positive cells/total number of cells of the same type) × 100).
In silico analysis of the TCGA dataset
Relative expression levels of indicated mRNAs were assessed using the TCGA dataset containing data from 1026 breast carcinoma patients (http://cancergenome. nih.gov). For the analysis, breast cancer samples were subdivided into three groups according to the level of brachyury (T) expression: 881 of 1026 samples with no detectable brachyury expression were classified as negative (neg). The remaining 145 samples were ranked and subdivided into 'brachyury-high' (high, 73 of 1026) and 'brachyury-low' (low, 72 of 1026) groups based on an arbitrary cutoff set at the median value for the 145 samples. The level of expression of mRNA encoding 
ER-α (ESR1), ER-β (ESR2), PR (PGR) and HER2 (ERBB2)
were evaluated in each group. A subset of tumors in the database (n = 513) for which data were available regarding the four intrinsic subtypes using the PAM50 discriminator assay (Parker et al. 2009 ) was further assessed for brachyury expression (Cancer Genome Atlas Network 2012). Samples were also subdivided into subgroups according to ER, PR and HER2 status for comparison of the levels of mRNAs encoding for brachyury, various EMT transcription factors and the chemokine IL8. Samples were classified as triple positive (ER+, PR+ and HER2+), TNBC (ER−, PR− and HER2−) and non-TNBC. Non-TNBC corresponds to tumors that were at least positive for one marker (ER, PR or HER2). All data were analyzed using the Nexus Expression 3 analysis software package (BioDiscovery).
Immunofluorescence
Tumor cells were cultured in 96-well black, clearbottom plates (Greiner Bio-One). After fixation with 3% paraformaldehyde (Electron Microscopy sciences), permeabilization with 0.05% Triton X and blockade by 1X PBS supplemented with 1% BSA and 10% goat serum, cells were stained using antibodies reactive against vimentin (Dako), fibronectin, ZO1 (BD Biosciences, San Jose, CA, USA), and brachyury (MAb 54-1) and Alexa Fluor 488 anti-mouse or anti-rabbit secondary antibodies. Nuclei were stained using DAPI (Thermo Fisher Scientific), and images were acquired using a Celigo S Cell Imaging Cytometer (Nexcelom Bioscience, Lawrence, MA, USA).
To silence brachyury expression, control and brachyurytargeting ON-TARGETplus SMARTpool siRNAs were purchased from Dharmacon and used according to the manufacturer's instructions (GE Life Sciences, Pittsburgh, PA, USA). Cells were incubated for 72 h in an antibioticfree medium before it is used in the analysis of various markers by immunofluorescence.
Quantitative real-time PCR
Total RNA was prepared using the PureLink RNA Mini Kit (Thermo Fisher Scientific) and reverse-transcribed with the XLAScript cDNA MasterMix (WordWide Life Sciences). The resulting cDNA (10 ng) was amplified in triplicate with the following TaqMan human gene expression assays (Life Technologies): T (brachyury) (Hs00610080_m1) and GAPDH (4326317E) using a 7300 Applied Biosystems instrument. Expression of brachyury relative to GAPDH was calculated as 2 −(Ct(GAPDH) − Ct(target gene)) . 
Statistical methods
The unpaired two-sample Student's t-test was used for comparison of mean expression levels of indicated transcripts in samples in the TCGA dataset. For survival analysis, samples for which clinical follow-up was available (n = 58) were assigned into a low vs high brachyury group, based on an arbitrary cutoff of 240 for the overall brachyury reactivity index, set at the 75th percentile for the overall population (n = 87). A KaplanMeier analysis was used to evaluate the association between brachyury expression and relapse-free survival.
Cox proportional hazards regression model was used to adjust for potential confounding factors such as stage of disease and p53 expression. All statistical tests were two sided.
Results
Brachyury mRNA expression in TNBC
Samples (n = 1026) from the TCGA breast cancer database were subdivided according to the level of brachyury (T) mRNA expression into brachyury negative (n = 881), low (n = 72) or high (n = 73) groups, and subsequently analyzed for the level of expression of ER-, PR-and HER2 receptorencoding mRNAs. The most significant associations were observed with ER-α-and PR-encoding mRNAs . Statistics were calculated using an unpaired t-test (*P < 0.05; ***P < 0.001; ****P < 0.0001; ns, not significant).
(ESR1 and PGR, respectively), which demonstrated a marked decrease of expression with increasing levels of brachyury (Fig. 1A) . However, this reverse association was not seen in relation to HER2-or ER-β encoding mRNAs (ERBB2 and ESR2, respectively, Fig. 1A ). (Fig. 1B) . Brachyury mRNA expression was also evaluated in samples from the same dataset stratified based on the POM50 gene signature (Parker et al. 2009 , Cancer Genome Atlas Network 2012 . As shown in Fig. 1C In addition to brachyury, the TCGA dataset was used to interrogate the expression of various transcription factors known to induce EMT. Although brachyury (T) mRNA was predominantly expressed in TNBC (47 of 101) vs triple-positive (3 of 88) breast carcinoma samples, only a slight increase of SNAI1, a decrease of ZEB1 and no changes in the mRNA levels of TWIST1, SNAI2 or ZEB2 were observed in TNBC vs triple-positive breast tumors (Fig. 1D) . Interestingly, we also noted a significant increase in IL8 mRNA levels in TNBC vs triplepositive breast tumors (Fig. 1E) , a result in support of our previous studies demonstrating a positive association between brachyury and the IL8 axis in breast cancer (Fernando et al. 2011) . 
Brachyury protein in primary and metastatic TNBC
Brachyury protein expression was assessed by IHC in 87 tumor tissues from patients diagnosed with TNBC by using a rabbit monoclonal anti-brachyury antibody (MAb 54-1) as described previously . Among 77 primary TNBC tumors, 71 of 77 (92%) showed some level of brachyury expression in >10% of the cancer cells, either in the nucleus or the cytoplasmic compartment ( Table 2) . As previously reported with other types of carcinomas, expression of brachyury was highly variable among primary tumors, with the percentage of brachyury-positive cells ranging from 10 to 100% and the intensity of staining varying between (+) and (+++). Representative images of two primary TNBC cases positive vs negative for brachyury expression are shown in Fig. 2A and B, respectively. In addition to primary tumors, brachyury expression was evaluated in metastatic lesions from 10 patients with TNBC (Table 3 and representative images in Fig. 2C-F) . Brachyury was observed in 100% of metastasis cases, the majority of cases showing high-intensity staining for brachyury (+++) in 40-100% of the tumor cells. Expression of brachyury was also evaluated in breast tissues adjacent and distant to the tumor. As shown in Fig. 3 , a gradient of expression was observed with the highest degree of brachyury positivity detected in the tumor > adjacent breast > distant breast tissue. In the examples shown in Fig. 3A and D, the primary tumor overall nuclear and cytoplasmic brachyury staining ranged from 20 to 80% of the cancer cells, whereas expression in breast tissues adjacent vs distal to tumor corresponded to approximately 10% ( Fig. 3B and E) and <5% ( Fig. 3C and F ) of the cells, respectively. Similarly, brachyury expression in the primary tumor shown in Fig. 3G corresponded to 80% of the cells, whereas expression in histologically normal breast tissue from the same patient demonstrated <1% positivity for brachyury (Fig. 3H) . These results are in agreement with our previous study using a different antibrachyury monoclonal antibody (Palena et al. 2014b) , in which brachyury-positive cells were observed in the breast tissue adjacent (15 of 27 cases) but not distal to the tumor, whereas no expression was detected in 14 benign breast tissues. The findings had an exception of two fibroadenoma cases in which focal expression of brachyury was observed. At present, it is unknown whether brachyury-expressing cells in the tissues adjacent to the tumor are cancer cells that have migrated toward the surrounding stroma or correspond to normal stromal cells that upregulated brachyury in response to tumorderived secreted factors.
In agreement with previous studies, brachyury protein was observed either in the nucleus and/or the cytosol of the TNBC cells. A comparative analysis of brachyury expression demonstrated a significant increase in nuclear brachyury protein levels, as detected by an increased reactivity index, in metastatic vs primary tumor samples (P = 0.02, Fig. 4A ), an association that was not observed with cytoplasmic brachyury. A similar association between nuclear localization of brachyury and clinical stage of disease was also observed, with samples from higher tumor stages (III-IV) having higher 
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nuclear brachyury reactivity index (P = 0.012) than samples of stage I (Fig. 4B ). The same difference was observed when combined samples from tumors stages I to II were compared with those of stages III-IV in which nuclear expression of brachyury was significantly higher in tumors of advanced stages, both in terms of reactivity index (P = 0.02) and % positive nuclei (P = 0.007, Fig. 4C ). This is a correlation that was not observed with cytoplasmic brachyury expression (Fig. 4D ).
Brachyury and TNBC prognosis
To evaluate a potential association of brachyury expression in primary TNBC with prognosis, samples for which clinical follow-up was available (n = 58) were assigned into low vs high brachyury groups. It was 
P=0.03
Figure 5 Brachyury expression and prognosis. Kaplan-Meier estimates of recurrence-free survival in 58 cases of TNBC classified based on the brachyury expression level. The two groups (low vs high brachyury) were defined based on the overall brachyury reactivity index set at a cutoff of 240, corresponding to the 75th percentile of expression in the overall population (n = 87). a Categorized according to an arbitrary cutoff calculated as the 75th percentile of brachyury reactivity index for total brachyury staining in the overall population (n = 87).
done based on an arbitrary cutoff of 240 for the overall brachyury reactivity index, set at the 75th percentile for the overall population (n = 87). A Kaplan-Meier estimate of survival showed that high brachyury expression in the primary tumor is significantly associated with decreased survival (P = 0.03, n = 58, long-rank test = 2.17, Fig. 5 ). To minimize the effect of clinical-pathological variables that might cause false-positive association between brachyury and poor prognosis, a multivariate Cox proportional hazards regression survival analysis was conducted. It was found that high brachyury expression (reactivity index ≥240) significantly associates with low relapse-free survival (P = 0.047, n = 58, COXPH, HR = 3.92, CI = 1.02-15.1), compared with the low brachyury expression group (Table 4) .
Brachyury expression in TNBC cell lines
Immunofluorescent staining of mesenchymal vimentin and epithelial ZO1 proteins was used for phenotypic confirmation of a panel of TNBC (MDA-MB-231, MDA-MB-436 and Hs578T) and non-TNBC (BT-474, ZR-75-1 and MCF7) human breast carcinoma lines. As expected, strong expression of mesenchymal vimentin and little expression of epithelial ZO1 were observed with TNBC cells, whereas non-TNBC cells showed high amounts of ZO1 in the absence of vimentin expression (Fig. 6A) . When expression of brachyury mRNA was evaluated in each cell line, higher levels were observed in TNBC vs non-TNBC cells (Fig. 6B) . The potential role of brachyury in tumor EMT was also investigated with MDA-MB-436 
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cells, in which silencing of brachyury resulted in reduced expression of vimentin and fibronectin and increased expression of epithelial ZO1 (Fig. 6C ). These observations thus suggested that brachyury not only associates with but is also required to maintain a mesenchymal-like phenotype in the MDA-MB-436 triple-negative breast cancer cell line.
Discussion
Elucidation of novel, potential therapeutic targets for the treatment of TNBC remains an urgent need in the absence of current, effective treatment for this aggressive tumor type. Our group and others have previously described the selective expression of the transcription factor brachyury, an immunotherapy target and a driver of tumor EMT (Palena et al. 2007 , Fernando et al. 2010 , Palena et al. 2014a , in primary and metastatic lesions of invasive ductal carcinomas of the breast (Palena et al. 2014b , Shao et al. 2015 . In this study, we further expanded those previous observations and demonstrated for the first time a prevalent expression of brachyury mRNA and protein in TNBC compared with other breast cancer subtypes. Variable levels of brachyury protein were observed by IHC in approximately 90% of primary and 100% of metastatic TNBC lesions analyzed. However, expression of brachyury was highly variable among primary tumors, with the percentage of positive cells ranging from 10 to 100% and the intensity of staining varying between (+) and (+++). Based on the relevant role of brachyury in tumor dissemination and/or resistance to anticancer treatments, it is expected that a small fraction of brachyury-positive cells in a tumor mass could have a major impact in terms of clinical outcome. With this functional relevance of brachyury in mind, a tissue has been designated here as 'brachyury positive' if at least 10% of the cancer cells exhibited some level of staining.
It is important to point out that in addition to providing evidence of variable levels of brachyury expression in TNBC, the data presented here also indicate that some level of brachyury could be present in normal breast tissues adjacent or distal to the tumor. These results contrast with our previous observations, in which brachyury was not detected in normal breast tissues from patients with benign conditions (Palena et al. 2014b) . Two recently completed phase I clinical trials of a yeastbrachyury vaccine (Heery et al. 2015b) or a MVA-brachyury-TRICOM vaccine (Heery et al. 2015a ) demonstrated no evidence of any autoimmune occurrence in the presence of measurable brachyury-specific CD4+ and CD8+ T-cell responses, even in normal testis and thyroid tissues that were previously shown to express some level of the brachyury protein. However, the presence of brachyury in normal breast tissues surrounding TNBC raises concern that an autoimmune event against those tissues could take place in vaccinated patients. This warrants careful evaluation in future studies of brachyury-based vaccines.
Three cancer vaccine platforms against brachyury have been developed and two are currently undergoing phase I/II clinical evaluation , Gabitzsch et al. 2015 , Heery et al. 2015a . In phase I clinical studies, brachyury-based vaccines have demonstrated the ability to elicit CD8+ and CD4+ brachyury-specific T-cell immune responses in the blood of patients after vaccination. These brachyury-specific T cells are shown to produce IFNγ, IL2 and TNFα and/or to express CD107a, a marker of lytic potential. Although some evidence of clinical response was observed, the small number of patients evaluated precluded the analysis of any potential association between the degree of antigen-specific immune response and clinical outcome. Further studies with larger number of patients need to be conducted to investigate whether such association could be established. In a previous report, we have shown that brachyury-specific T cells generated from the blood of cancer patients can lyse basal MDA-MB-231 cancer cells in an MHC-restricted manner (Palena et al. 2014b) . Those experiments were conducted with unfractionated CD8+ T cells, and it is expected that a higher degree of lysis would be observed with tetramerisolated, brachyury-specific T cells.
Although the molecular classification of breast cancer into various subtypes has revealed a high degree of heterogeneity in this disease, the majority of TNBC cases (56-95%) can be molecularly categorized as basallike (Prat et al. 2012) . Tumors of this subtype are defined by the expression of genes typically present in normal breast basal/myoepithelial cells and are characterized by a high proliferation index, p53 mutations and an aggressive course with frequent tumor relapse (Reis-Filho & Tutt 2008) . The phenomenon of EMT, a phenotypic switch that allows epithelial cells to acquire motility, invasiveness and resistance to cell death while exhibiting features characteristic of mesenchymal cells, is being postulated as a relevant mechanism that fosters progression toward metastatic disease (Kalluri & Weinberg 2009 ). In agreement, it is the aggressive basal-like group of breast cancer that commonly exhibits mesenchymal features,
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including expression of vimentin, smooth-muscle-actin (SMA) and N-cadherin in place of epithelial E-cadherin (Blick et al. 2008 , Sarrio et al. 2008 .
The transcription factor brachyury has been previously shown to induce phenotypic changes in carcinoma cells reminiscent of an EMT, a phenomenon associated with tumor dissemination, metastasis and acquisition of resistance to a variety of antitumor therapies , Larocca et al. 2013 . In this regard, we and others have shown that the presence of high levels of brachyury in the primary tumor can predict poor prognosis in a range of human carcinomas including lung (Haro et al. 2013) , hepatocellular (Du et al. 2014) , GIST (Pinto et al. 2015) , prostate (Pinto et al. 2014) , colorectal (Kilic et al. 2011 , Sarkar et al. 2012 and hormone receptor-positive breast cancer (Palena et al. 2014b) . In agreement, here we have observed that high levels of brachyury in primary TNBC tumors associate with poor survival. However, it is important to point out that studies of the association between brachyury and patient survival were based on an arbitrary cutoff of ≥240 for the brachyury reactivity index. Thus, expression of brachyury in primary TNBC is proposed to be a bad prognostic indicator only for the fraction of tumors that express brachyury in at least 80% of the cancer cells and at high staining intensity (+++), which will result in reactivity index values ≥240.
In our previous studies, we have conducted gain-and loss-of-function experiments to investigate the particular role of brachyury in breast carcinoma cells. Using basallike, hormone-receptor-negative MDA-MB-436 cells, we have shown that silencing of brachyury is able to significantly reduce cell invasiveness and the tumor cells' ability to form mammospheres in primary and secondary cultures, a measure of tumor stemness, relative to their control counterparts. The loss of brachyury was also shown to significantly sensitize basal-like MDA-MB-436 cells to the cytotoxic activity of docetaxel, thus demonstrating a potential role for brachyury in tumor invasiveness and resistance to cell death in TNBC (Palena et al. 2014b) . A recent report (Ben-Hamo et al. 2014) has identified brachyury as a dominant gene in a network of genes that most significantly discriminate TNBC from non-TNBC samples. Here, we have further demonstrated the prevalent expression of brachyury in a panel of TNBC human breast carcinoma cell lines and validated its role as a driver of tumor EMT with MDA-MB-436 TNBC cells, in which brachyury silencing markedly reduced the expression of mesenchymal vimentin and fibronectin, whereas increased the expression of epithelial ZO1.
In this study, the expression of brachyury mRNA was shown to be predominant among TNBC vs triple-positive samples in the TCGA database, whereas that was not the case with other EMT drivers, including TWIST1, SNAI2 or ZEB2 mRNA. These results seemed to contradict the expected enrichment of EMT markers in TNBC samples. Although the reason for these observations is unknown at this time, we have previously observed that expression of TWIST1, SNAI1 and SNAI2 mRNA is detectable in normal tissues at levels comparable with those observed in tumors (Roselli et al. 2012 , Palena et al. 2014b . As the mRNA analysis includes not only tumor cells but also surrounding normal tissues, one possible explanation for the absence of difference of expression of the EMT markers between different tumor types could be the simultaneous detection in adjacent normal cells. Unlike TWIST1, SNAI1 and SNAI2, we have previously shown that expression of brachyury mRNA is undetectable in normal breast tissues (Palena et al. 2014b) .
Among genes that were differentially expressed between TNBC and other tumors was IL8, a chemokine that was previously associated with tumor stemness and EMT in breast cancer (Ginestier et al. 2010 , Fernando et al. 2011 , Palena et al. 2012 . We have previously demonstrated that IL8 is able to significantly upregulate brachyury expression in breast cancer cells at the transcriptional level and that upregulation of brachyury leads to increased secretion of IL8 and overexpression of IL8 receptors. It thus establishes an autocrine feedforward loop that sustains the mesenchymal, resistant phenotype. We hypothesize that the presence of this autocrine regulatory loop in TNBC could drive the expression of brachyury and, potentially, the acquisition of mesenchymal and stem-like features by the tumor cells.
Although there have been some discrepancies regarding the detection of brachyury protein in various types of carcinomas, we believe that these inconsistencies are due to the utilization of various antibodies possessing a range of affinity and specificity for the target protein brachyury. We and others have shown that brachyury can be detected in the nucleus and/or the cytosol of carcinoma cells, whereas its expression in chordomas is predominantly seen in the nucleus of the tumor cells (Pinto et al. 2014 , Miettinen et al. 2015 . In agreement with those previous observations, here we demonstrated that brachyury protein can be detected either in the nucleus and/or the cytosol of TNBC cells, although their expression is somehow linked with a positive correlative trend observed between the nuclear 23:10 and cytoplasmic reactivity index (r = 0.236, P = 0.04). Although the biological relevance of nuclear vs cytosolic brachyury localization in tumor cells remains unknown, it was interesting to observe in this study that nuclear (but not cytosolic) expression of brachyury is associated with clinical stage of disease and was more predominant in metastatic vs primary tumor tissues. This potentially indicates a role for brachyury in tumor progression when localized in the nucleus, where its transcriptional activity is expected to take place. Future studies are warranted to evaluate, in a larger cohort of TNBC patients, the potential association between nuclear vs cytoplasmic brachyury expression and clinical outcome.
Altogether our observations demonstrate the potential of brachyury as a target for the treatment of early or metastatic TNBC and provide rationale for using a brachyury-targeting vaccine approach for treatment of this disease.
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